# Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease

> **NCT06446219** · — · COMPLETED · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 172 (actual)

## Conditions studied

- Crohn Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06446219
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-01
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446219, "Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06446219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*